Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers

Cancer Research

Volumn 71, Issue 18, 2011, Pages 5987-5997

  Pittoni, Paola ^a   Tripodo, Claudio ^b   Piconese, Silvia ^a,c   Mauri, Giorgio ^a   Parenza, Mariella ^a   Rigoni, Alice ^a   Sangaletti, Sabina ^a   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; CARCINOMA; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NEUROENDOCRINE CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; CARCINOMA, NEUROENDOCRINE; CELL DEGRANULATION; CELL LINE, TUMOR; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; MAST CELLS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; TUMOR MICROENVIRONMENT;

EID: 80052818509     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1637     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996;180: 295-9. (Pubitemid 26393679)
3. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009;16:37-44.
4. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
5. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol 2001;Chapter 20:Unit 20.5.
6. Tang Y, Wang L, Goloubeva O, Khan MA, Lee D, Hussain A. The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. Prostate 2009;69:1763-73.
7. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004;25:235-41. (Pubitemid 38501669)
8. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009;1796:19-26.
9. Sari A, Serel TA, Candir O, Ozturk A, Kosar A. Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma. BJU Int 1999;84:851-3. (Pubitemid 29500055)
10. Simak R, Capodieci P, Cohen DW, Fair WR, Scher H, Melamed J, et al. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histol Histopathol 2000;15:365-74. (Pubitemid 30218829)
11. Aydin O, Dusmez D, Cinel L, Doruk E, Kanik A. Immunohistological analysis of mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma compared to benign prostatic hyperplasia. Pathol Res Pract 2002;198:267-71. (Pubitemid 34495573)
12. Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, et al. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 2007;97:952-6. (Pubitemid 47519307)
13. Fleischmann A, Schlomm T, Kollermann J, Sekulic N, Huland H, Mirlacher M, et al. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 2009;69: 976-81.
14. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 2010;177:1031-41.
15. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-30. (Pubitemid 27355467)
16. Wirtzfeld LA, Wu G, Bygrave M, Yamasaki Y, Sakai H, Moussa M, et al. A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res 2005;65:6337-45. (Pubitemid 40994420)
17. Piconese S, Costanza M, Musio S, Tripodo C, Poliani PL, Gri G, et al. Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient Kit(W-sh/W-sh) mice. Lab Invest 2011;91: 627-41.
18. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Aminobiphosphonate- mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007;67:11438-46. (Pubitemid 350248572)
19. + regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008;29:771-81.
20. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294-9. (Pubitemid 10140274)
21. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet 2006;38:500-1.
22. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64:2270-305.
23. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13:1382-97. (Pubitemid 29270244)
24. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13:1211-8. (Pubitemid 47530639)
25. Thompson PJ, Hanson JM, Morley J. Asthma, mast cells, and sodium cromoglycate. Lancet 1983;2:848-9. (Pubitemid 13009278)
26. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005;167:835-48. (Pubitemid 41216366)
27. Nigrovic PA, Gray DH, Jones T, Hallgren J, Kuo FC, Chaletzky B, et al. Genetic inversion in mast cell-deficient (W(sh)) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. American J Pathol 2008;173:1693-701.
28. Norrby K. Mast cells and angiogenesis. APMIS 2002;110:355-71.
29. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol 1999;29:2645-9.
30. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol 2001; 167:4008-16. (Pubitemid 32910846)
31. Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002;277: 44462-74. (Pubitemid 36157881)
32. Ippolito JE, Xu J, Jain S, Moulder K, Mennerick S, Crowley JR, et al. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci U S A 2005;102:9901-6. (Pubitemid 40993665)
33. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H Cardiff RD, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172: 236-46. (Pubitemid 351186384)
34. Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, et al. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007;9:938-50. (Pubitemid 350086439)
35. Leong KG, Wang BE, Johnson L, Gao WQ. Generation of a prostate from a single adult stem cell. Nature 2008;456: 804-8.
36. Groot Kormelink T, Abudukelimu A, Redegeld FA. Mast cells as target in cancer therapy. Curr Pharma Design 2009;15: 1868-78.
37. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-90.
38. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, et al. Activation of the osteopontin/matrix metalloproteinase- 9 pathway correlates with prostate cancer progression. Clin Cancer Res 2008;14:7470-80.
39. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 2010;70:2224-34.
40. Goldstein AS, Stoyanova T, Witte ON. Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol 2010;4:385-96.
41. Jin Y, Silverman AJ, Vannucci SJ. Mast cell stabilization limits hypoxic- ischemic brain damage in the immature rat. Dev Neurosci 2007;29:373-84. (Pubitemid 47343691)
42. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011;121:1298-312.
43. Di Lorenzo G, Autorino R, D'Armiento FP, Mignogna C, De Laurentiis M, De Sio M, et al. Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 2004;30:987-92. (Pubitemid 39462531)
44. Kostoula V, Khan K, Savage K, Stubbs M, Quaglia A, Dhillon AP, et al. Expression of c-kit (CD117) in neuroendocrine tumours-a target for therapy? Oncol Rep 2005;13:643-7.
45. Pittoni P, Piconese S, Tripodo C, Colombo MP. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 2010;30:757-69.